In the most severe infantile form, complete or near-complete deficiency of the enzyme manifests as cardiomegaly, hypotonia, and mild hepatomegaly, resulting in death within the first year due to cardiorespiratory failure. Residual enzyme activity in milder late-onset variants spares cardiac involvement. The predominant

manifestations of the late-onset form include slowly progressive proximal myopathy with respiratory muscle involvement; respiratory failure is the cause of significant morbidity and mortality. Inhibitors,research,lifescience,medical The efficacy of ERT with recombinant human GAA (rhGAA) has been extensively studied in pre-clinical trials and in a relatively small group of Pompe patients with the most severe infantile phenotype. Infantile patients enrolled in the first clinical trials with alglucosidase alfa (Myozyme®; Genzyme Corp., Framingham, MA) survived significantly longer than expected for untreated patients Inhibitors,research,lifescience,medical because of greatly improved cardiac function, but only a small subset achieved significant improvement in skeletal muscle function and mortality was still high (5–8). Nine of seventeen infants enrolled in different trials died from disease complications Inhibitors,research,lifescience,medical (8). Thus, ERT has not been the magic medicine hoped for: skeletal muscle has turned out to

be a difficult target. Experiments in a knockout mouse model of Pompe disease with the replacement enzyme pointed to the same problem: poor NSC-330507 response to therapy in skeletal muscle (9, 10). In mice, it quickly became apparent that type II skeletal muscle fibers are resistant to therapy (10). These fibers Ponatinib TNKS1 showed very modest glycogen reduction on high doses of the therapeutic enzyme despite the fact that

in untreated mice, type II fibers accumulated much less glycogen Inhibitors,research,lifescience,medical compared to cardiac and type I – rich muscle. Thus, paradoxically, the effectiveness of therapy does not wholly depend on the amount of storage material. Therefore we explored the differences between glycolytic fast-twitch type Inhibitors,research,lifescience,medical II and oxidative slow-twitch type I fibers. We have found differences in the distribution of lysosomes in both wild-type (WT) and knockout (KO) fibers: in type I fibers, the lysosomes are lined up and appear connected, while in type II fibers the lysosomes are randomly Cilengitide distributed and do not touch. We have also found that type II fibers have lower levels of the proteins involved in endocytosis and lysosomal targeting of the therapeutic enzyme, such as the cation-independent mannose-6-phosphate receptor (10, 11). This receptor, located in the cytosol and on the cell surface, is responsible for the uptake of the recombinant enzyme and its delivery to the late endocytic compartment. While these fiber-type specific properties may contribute to the differential response to therapy, the “elephant in the room” was the presence of large areas of autophagic buildup in type II fibers.